JPWO2020142780A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020142780A5
JPWO2020142780A5 JP2021537208A JP2021537208A JPWO2020142780A5 JP WO2020142780 A5 JPWO2020142780 A5 JP WO2020142780A5 JP 2021537208 A JP2021537208 A JP 2021537208A JP 2021537208 A JP2021537208 A JP 2021537208A JP WO2020142780 A5 JPWO2020142780 A5 JP WO2020142780A5
Authority
JP
Japan
Prior art keywords
receptor
antigen
protein
pharmaceutical composition
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021537208A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022516710A5 (https=
JP2022516710A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/012417 external-priority patent/WO2020142780A1/en
Publication of JP2022516710A publication Critical patent/JP2022516710A/ja
Publication of JPWO2020142780A5 publication Critical patent/JPWO2020142780A5/ja
Publication of JP2022516710A5 publication Critical patent/JP2022516710A5/ja
Pending legal-status Critical Current

Links

JP2021537208A 2019-01-06 2020-01-06 Car t細胞の方法及び構築物 Pending JP2022516710A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962788894P 2019-01-06 2019-01-06
US62/788,894 2019-01-06
PCT/US2020/012417 WO2020142780A1 (en) 2019-01-06 2020-01-06 Car t cell methods and constructs

Publications (3)

Publication Number Publication Date
JP2022516710A JP2022516710A (ja) 2022-03-02
JPWO2020142780A5 true JPWO2020142780A5 (https=) 2023-01-19
JP2022516710A5 JP2022516710A5 (https=) 2023-01-19

Family

ID=71406633

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021537208A Pending JP2022516710A (ja) 2019-01-06 2020-01-06 Car t細胞の方法及び構築物

Country Status (13)

Country Link
US (1) US20220090132A1 (https=)
EP (1) EP3906311A4 (https=)
JP (1) JP2022516710A (https=)
KR (1) KR20210137427A (https=)
CN (1) CN113382741A (https=)
AU (1) AU2020205000A1 (https=)
BR (1) BR112021013180A2 (https=)
CA (1) CA3125201A1 (https=)
IL (1) IL284461A (https=)
PH (1) PH12021551619A1 (https=)
SG (1) SG11202107246TA (https=)
WO (1) WO2020142780A1 (https=)
ZA (1) ZA202103899B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12419913B2 (en) 2019-02-08 2025-09-23 Dna Twopointo, Inc. Modification of CAR-T cells
WO2025084880A1 (ko) * 2023-10-20 2025-04-24 주식회사 이온셀 Ct83 항원에 결합하는 car-t 세포 및 이의 용도
CN117567650B (zh) * 2024-01-15 2024-04-02 中国人民解放军东部战区总医院 共表达细胞间黏附分子icam2的car-t细胞及其制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998000541A2 (en) * 1996-07-03 1998-01-08 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of human disease
CA2371216A1 (en) * 1999-04-23 2000-11-02 Centre For Translational Research In Cancer Pseudotyped retroviral vector for gene therapy of cancer
AU2001265187A1 (en) * 2000-05-30 2001-12-11 Baylor College Of Medicine Chimeric viral vectors for gene therapy
US20130266551A1 (en) * 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
GB201322798D0 (en) * 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
US11230719B2 (en) * 2014-03-26 2022-01-25 Denovo Biopharma Llc Retroviral vector having immune-stimulating activity
AU2016243124A1 (en) * 2015-03-27 2017-11-02 University Of Southern California CAR T-cell therapy directed to LHR for the treatment of solid tumors
EP3286225B1 (en) * 2015-04-23 2020-07-01 Baylor College of Medicine Cd5 chimeric antigen receptor for adoptive t cell therapy
CN107708741A (zh) * 2015-06-12 2018-02-16 免疫医疗公司 用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法
MA46236A (fr) * 2016-09-14 2019-07-24 Janssen Biotech Inc Récepteurs antigéniques chimériques comprenant des domaines de la fibronectine de type iii spécifiques du bcma, et utilisations correspondantes
CA3068634A1 (en) * 2017-06-30 2019-01-03 Memorial Sloan Kettering Cancer Center Compositions and methods for adoptive cell therapy for cancer

Similar Documents

Publication Publication Date Title
JP2021525509A5 (https=)
IL273201B1 (en) Novel platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy
JPWO2021188599A5 (https=)
JP2025037871A5 (https=)
JP2021500861A5 (https=)
DK3012268T3 (en) Chimeric antigen receptors with an optimized hinge region
JP2020500530A5 (https=)
JP2023518049A (ja) 新規な抗原結合ドメインおよびそれを組み込んだ合成抗原受容体
IL321733A (en) Compositions and methods for selective degradation of proteins
JPWO2019232503A5 (https=)
CN113227379A (zh) 多功能多靶向嵌合抗原受体(car)系统及其使用方法
RU2018122106A (ru) Буферы для стабилизации лентивирусных препаратов
US20230028399A1 (en) Bcma-directed cellular immunotherapy compositions and methods
IL297514A (en) Vectors and methods for in vivo transduction
JP2019518424A5 (https=)
HRP20230457T1 (hr) Pripravci i postupci za selektivnu ekspresiju kimernih antigenskih receptora
US20210095029A1 (en) Compositions and methods for treating cancer
FI3380620T3 (fi) Optimoituja lentiviruksen siirtovektoreita ja niiden käyttötapoja
JP2020517263A5 (https=)
IL297547A (en) Therapeutic interventional particles for the corona virus
JP2021532742A5 (https=)
JPWO2022178367A5 (https=)
CN110511912A (zh) 免疫细胞的功能调节
EP4232566A1 (en) Chimeric activation receptors
JP2022516710A (ja) Car t細胞の方法及び構築物